SCHEMBL23844012

SCHEMBL23844012

COC(C)(C)COC(=O)[C@H](C)NC(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA12 O43570 1/20 0.42
CA14 Q9ULX7 1/20 0.42
CYP2D6 P10635 1/20 0.41
KMT2A Q03164 1/20 0.40
CTSK P43235 7/20 0.39
CTSS P25774 3/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
EPHX2 P34913 1/20 0.38
CTSL P07711 1/20 0.38
CTSB P07858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28986534 0.98 CA1 (0.44) CA1CA2CA7CA12CA14
Hydrochloric Acid SCHEMBL28986535 0.98 CA1 (0.44) CA1CA2CA7CA12CA14
SCHEMBL20854166 0.85 CA1 (0.49) CA1CA2CA7CA12CA14
SCHEMBL20854165 0.85 CA1 (0.49) CA1CA2CA7CA12CA14
SCHEMBL23819151 0.83 CA1 (0.47) CA1CA2CA7CA12CA14
SCHEMBL28197702 0.82 CA1 (0.46) CA1CA2CA7CA12CA14
SCHEMBL23075803 0.82 CA1 (0.46) CA1CA2CA7CA12CA14
SCHEMBL19236548 0.82 CA1 (0.46) CA1CA2CA7CA12CA14
SCHEMBL241988 0.81 CA14 (0.59) CA1CA2CA7CA12CA14
SCHEMBL2380555 0.81 CA14 (0.59) CA1CA2CA7CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES INC (US) 2026-02-05 US disclosed
EP-4644394-A2 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2025-11-05 EP disclosed
EP-4106876-B1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES INC (US) 2025-09-17 EP disclosed
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2025-09-02 US disclosed
US-20250002513-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2025-01-02 US disclosed
CN-118598916-A Antiviral compounds 吉利德科学公司 2024-09-06 CN disclosed
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-29 US disclosed
US-12030903-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2024-07-09 US disclosed
US-12030903-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2024-07-09 US disclosed
CN-115135383-B Antiviral compounds 吉利德科学公司 2024-06-11 CN disclosed
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof GILEAD SCIENCES, INC. (US) 2024-03-26 US disclosed
EP-4172160-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2023-05-03 EP disclosed
CN-115996928-A 1' -cyanonucleoside analogs and uses thereof 吉利德科学公司 2023-04-21 CN disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 US disclosed
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. 2023-02-09 US disclosed
EP-4106876-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-28 EP disclosed
CN-115135383-A Antiviral compounds 吉利德科学公司 2022-09-30 CN disclosed
WO-2021262826-A2 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2021-12-30 WO disclosed
US-20210292348-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030903-B2 Antiviral compounds EIF2AK2, MAVS, DUT CA1 4883/4885CA2 4733/4885CA7 4448/4885
US-20240287109-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT CA1 2325/4885CA2 3176/4885CA7 1603/4885
US-20250002513-A1 ANTIVIRAL COMPOUNDS EIF2AK2, MAVS, DUT CA1 4883/4885CA2 4733/4885CA7 4448/4885
US-12404289-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT CA1 2722/4885CA2 3347/4885CA7 1713/4885
US-20210292348-A1 ANTIVIRAL COMPOUNDS EIF2AK2, MAVS, DUT CA1 4883/4885CA2 4733/4885CA7 4448/4885
US-20230040586-A1 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF TYMP, PNP, DUT CA1 2325/4885CA2 3176/4885CA7 1603/4885
US-11939347-B2 1′-cyano nucleoside analogs and uses thereof TYMP, PNP, DUT CA1 2722/4885CA2 3347/4885CA7 1713/4885
US-20260035394-A1 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF PNP, SLC28A1, SLC29A1 CA1 1691/4885CA2 356/4885CA7 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.